

**NOTICE TO THE HOLDERS (THE "BONDHOLDERS") OF THE S\$90,000,000 3.54 PER CENT. SENIOR UNSECURED GUARANTEED BONDS DUE 2029 UNCONDITIONALLY AND IRREVOCABLY GUARANTEED BY CREDIT GUARANTEE AND INVESTMENT FACILITY, A TRUST FUND OF THE ASIAN DEVELOPMENT BANK ISSUED BY SINGAPORE MEDICAL GROUP LIMITED (THE "BONDS")**

---

**ENTRY INTO SALE AND PURCHASE AGREEMENT IN RELATION TO THE DIVESTMENT OF SHARES HELD BY SINGAPORE MEDICAL GROUP LIMITED IN EACH OF LIFESCAN IMAGING PTE. LTD., NOVENA RADIOLOGY PTE. LTD. AND FARRER PARK RADIOLOGY PTE. LTD.**

---

**1. INTRODUCTION**

**1.1.** The Board of Directors (the "**Board**") of Singapore Medical Group Limited (the "**Issuer**") wishes to announce that the Issuer has entered into a share purchase agreement (the "**SPA**") with a third party (the "**Purchaser**") on 11 June 2026, in relation to the proposed sale and purchase of:

- (a) the entire issued share capital of Lifescan Imaging Pte. Ltd. ("**Lifescan Imaging**");
- (b) all of the shares in the issued share capital of Novena Radiology Pte. Ltd. ("**Novena Radiology**") held by the Issuer; and
- (c) the entire issued share capital of Farrer Park Radiology Pte. Ltd. ("**Farrer Park Radiology**", together with Lifescan Imaging and Novena Radiology, the "**Target Companies**"),

(the "**Divestment**").

The remaining shares in the issued share capital of Novena Radiology are held by Lifescan Imaging.

**1.2.** The Purchaser is a Singapore headquartered private healthcare services provider with strategic focus on business areas that are highly complementary with those of the Target Companies.

**1.3** Upon completion of the Divestment, the Issuer will cease to hold any shares in the Target Companies.

**2. THE DIVESTMENT**

The Divestment will be for 100% cash consideration on a willing buyer, willing seller basis.

The Divestment is contingent upon the satisfaction and/or waiver of certain conditions precedent on or before the Long-Stop Date (as defined in the SPA).

**3. RATIONALE FOR THE DIVESTMENT**

The Divestment is part of the Group's strategic plans to optimise the Group's business portfolio and strengthen its strategic focus on other key specialist segments such as Women's Health and Reproductive Medicine. The Divestment will also enhance the Group's capital resources for future deployment in new expansion initiatives.

***Bondholders are advised to exercise caution in trading their Bonds as there is no certainty or assurance as at the date of this announcement that any discussions or prospects will be successfully concluded.***

***Bondholders are advised to read this announcement carefully and where in doubt as to the action they should take, they should consult their stock brokers, bank managers, solicitors, or other professional advisers.***

BY ORDER OF THE BOARD

Dr Beng Teck Liang  
Executive Director and Chief Executive Officer  
30 June 2026